Ligritinib vs Mecbotamab vedotin (CAB-AXL-ADC)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: AXL · full Non-Small Cell Lung Cancer pipeline

Ligritinib

Developed by Arcus Biosciences

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Mecbotamab vedotin (CAB-AXL-ADC)

Developed by BioAtla, Inc.

Phase 2 in Non-Small Cell Lung Cancerantibody-drug conjugate
Weak signal

NCT04681131 · Phase 2 · completed

The study was nonrandomized and open-label, with two experimental treatment groups and no placebo or active comparator. Its primary efficacy endpoint was objective tumor response assessed by RECIST. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Confirmed Objective Response Rate (ORR) per RECIST v1.1 (Up to 24 months); Incidence of Adverse Events (AEs)or Serious Adverse Events (SAEs) as assessed by CTCAE v4.03/v5 (Up to 24 months): BA3011 (CAB-AXL-ADC/mecbotamab vedotin) monotherapy in PD-1/L1-treatment-failure NSCLC patients evaluable at 12 weeks: ORR 27.8%, disease control rate 55.6%, median duration of response 4.8 months (range 2.3-12.1+ months) (not_applicable)

Result source: NCT04681131

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLigritinibMecbotamab vedotin (CAB-AXL-ADC)
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported27.8%abwk 12NCT04681131
Duration of response, median—Not reported4.8abwk 12NCT04681131

PFS, median

Ligritinib
—Not reported
Mecbotamab vedotin (CAB-AXL-ADC)
—Not reported

OS, median

Ligritinib
—Not reported
Mecbotamab vedotin (CAB-AXL-ADC)
—Not reported

ORR

Ligritinib
—Not reported
Mecbotamab vedotin (CAB-AXL-ADC)
27.8%abwk 12NCT04681131

Duration of response, median

Ligritinib
—Not reported
Mecbotamab vedotin (CAB-AXL-ADC)
4.8abwk 12NCT04681131
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ligritinib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Mecbotamab vedotin (CAB-AXL-ADC)

ORR 27.8% @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT04681131 · Phase 2 · sponsor-reported, not registry data
Disease Control 55.6% @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT04681131 · Phase 2 · sponsor-reported, not registry data
Duration of Response 4.8 months @ 12wk
time to event · months
No placebo or comparator arm
NCT04681131 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ligritinib's landscape · Mecbotamab vedotin (CAB-AXL-ADC)'s landscape